However, it is unclear whether a secondary AML ontogeny attribution and adverse prognostic impact can also be assigned to the less frequent cohesin complex mutations in SMC1A, SMC3, RAD21, and PDS5B [21]. This evidence concerns the gene SMC1A and acute myeloid leukemia.